GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

US advisers to consider RSV shots as GSK looks to keep market lead

The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time CEO Summit, boss Emma Walmsley said that even though only 3 per cent of its business is in Britain, GSK switching its listing was "not a debate for us.

GSK 100% backs London listing, says boss

Innoviva

Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio's computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the unders.

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease

GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug giant's decision to challenge a key US court ruling. The Delaware state court ruling allowed plaintiffs' expert testimony in Zantac trials, contrary to a previous Federal court decision dismissing all multi-district litigation (MDL) cases.

GSK 'still appealing' despite US legal setback says broker

GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer.  Analysts had expected the UK drug giant, along with Pfizer, Sanofi and Boehringer Ingelheim to contest the original ruling.

GSK appeals Delaware Zantac ruling

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk of severe outcomes from the cold-like infection. GSK estimates over 13 million US adults fall into this category.

GSK RSV jab receives label expansion from US regulator

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK's AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.

US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.  The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus.

FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach

The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age group.

US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59

Novo Nordisk

Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.

The 3 Most Undervalued Pharma Stocks to Buy in June 2024

What was supposed to be a stellar day for GSK PLC (LSE:GSK, NYSE:GSK) at the annual American Society of Clinical Oncology turned into quite the opposite. News of an adverse ruling in a Delaware court affecting long-running litigation over Zantac, the heartburn tablet linked cancer, overshadowed what was a very bullish read-out from a trial of its Blenrep drug in people suffering multiple myeloma.

GSK: Still reasons to be cheerful rather than fearful after 'nightmare' Monday

Many investors expected today's move in GlaxoSmithKline (NYSE: GSK ), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that expert witnesses would be allowed to testify in court that the company's discontinued Zantac heartburn medication may have caused cancer.

GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.

American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker's discontinued heartburn treatment, Zantac, causes cancer can go forward.

GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward

GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.

GSK Stock Dips on Delaware Court Ruling for Zantac Litigation

GSK plc (NYSE:GSK) faced a significant setback on June 3rd when its stock plunged by 8% following a Delaware judge's ruling allowing over 70,000 lawsuits against the company regarding its discontinued heartburn drug Zantac to proceed.

Is GSK stock a sell with 75,000 Zantac cases moving forward?

GSK shares plunged Monday after the Delaware State Court ruled that expert witnesses can present scientific evidence in the roughly 75,000 cases relating to the discontinued heartburn drug Zantac. The drug was manufactured and sold by several companies from the 1980s until 2020, when it was recalled over concerns it contained a probable carcinogen called NDMA.

Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits

PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer.

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as it focused on the long-term potential of the stock. After hours on Friday, the Delaware Superior Court allowed over 70,000 lawsuits related to the heartburn drug to proceed, creating a significant overhang for the pharmaceutical giant.

GSK: Zantac litigation obscures the positives, says leading investment bank

GSK shares dropped 10% after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition. GSK said it's going to appeal the decision.

GSK shares tumble 10% after Zantac ruling

Shares in British drugmaker GSK dropped more than 9% on Monday after a Delaware judge allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward.

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward

GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward. The ruling, from late on Friday by Judge Vivian Medinilla of the Delaware Superior Court, was that expert witnesses can testify in court that the drug may cause cancer.

GSK to appeal US judge's Zantac ruling

PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma.

Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

News for GlaxoSmithKline Stock (GSK)